KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Receivables (2016 - 2025)

Historic Receivables for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $5.8 billion.

  • Gilead Sciences' Receivables rose 2135.82% to $5.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 billion, marking a year-over-year increase of 2135.82%. This contributed to the annual value of $5.6 billion for FY2024, which is 1714.47% up from last year.
  • Latest data reveals that Gilead Sciences reported Receivables of $5.8 billion as of Q3 2025, which was up 2135.82% from $5.9 billion recorded in Q2 2025.
  • Gilead Sciences' 5-year Receivables high stood at $5.9 billion for Q2 2025, and its period low was $3.9 billion during Q1 2022.
  • Moreover, its 5-year median value for Receivables was $4.9 billion (2023), whereas its average is $5.0 billion.
  • Over the last 5 years, Gilead Sciences' Receivables had its largest YoY gain of 5234.54% in 2021, and its largest YoY loss of 1894.76% in 2021.
  • Quarter analysis of 5 years shows Gilead Sciences' Receivables stood at $4.7 billion in 2021, then rose by 6.02% to $4.9 billion in 2022, then fell by 3.46% to $4.8 billion in 2023, then increased by 17.14% to $5.6 billion in 2024, then increased by 3.47% to $5.8 billion in 2025.
  • Its Receivables stands at $5.8 billion for Q3 2025, versus $5.9 billion for Q2 2025 and $5.6 billion for Q1 2025.